Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARK7 | Q99497 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899362 | 0.91 | MEN1 (0.42) | ALDH1A1MEN1KMT2ARIPK1CYP1A2 | |
| SCHEMBL4899852 | 0.89 | ALDH1A1 (0.41) | OPRM1ALDH1A1POLBKDM4EMEN1 | |
| SCHEMBL4896111 | 0.82 | NPSR1 (0.41) | ALDH1A1MEN1KMT2A | |
| SCHEMBL4897407 | 0.81 | CYP1A2 (0.39) | ALDH1A1MEN1KMT2ARIPK1CYP1A2 | |
| SCHEMBL4897374 | 0.80 | PTGDR2 (0.41) | MEN1KMT2A | |
| SCHEMBL4897077 | 0.79 | RIPK1 (0.38) | ALDH1A1POLBMEN1KMT2ARIPK1 | |
| SCHEMBL4895747 | 0.79 | BRD4 (0.41) | ALDH1A1MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL5418185 | 0.79 | ALDH1A1 (0.40) | PARK7ALDH1A1KDM4EMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4897324 | 0.77 | PARK7 (0.40) | PARK7ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL4894380 | 0.75 | MEN1 (0.37) | POLBMEN1KMT2ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | PARK7 2794/4885OPRM1 3253/4885ALDH1A1 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.